The hepatitis C virus NS5A protein has been previously demonstrated to partially attenuate activation of the Ras-Erk signalling pathway, via a conserved class II polyproline motif located towards the C terminus of the protein. However, the role of Ras-Erk signalling in the virus life cycle remains undetermined. To investigate this, levels of RNA replication were measured in genotypes 1 and 2 transient luciferase subgenomic replicon systems in the context of either pharmacological or genetic (dominant-negative) inhibition of MEK1, a kinase in the Ras-Erk signalling cascade. Incubation in the presence of two inhibitors (U0126 and PD184352) resulted in a decrease in the levels of RNA replication, conversely incubation with inhibitor PD98059 resulted in a modest increase in replication. The results obtained with PD98059 could not be explained by an off-target effect on Cox-2, stability of replicon RNA or stimulation of global translation levels, suggesting stimulation by a yet uncharacterized mechanism. To verify data obtained using pharmacological inhibitors the transient replicon RNA was co-electroporated with a dominant-negative mutant of MEK1. This resulted in a reduction in replication, confirming data seen with U0126 and PD184352. Our data are consistent with the hypothesis that a low level Ras-Erk signalling activity is required for RNA replication. However, complete inhibition of Ras-Erk signalling is inhibitory. These results suggest that perturbation of this signalling pathway by NS5A may be a mechanism to regulate levels of genomic RNA replication.
INTRODUCTION
Hepatitis C virus (HCV), an enveloped single-stranded positive-sense RNA virus, is estimated to infect 3 % of the world's population. In the majority of patients it establishes a chronic infection, leading to liver fibrosis and cirrhosis, and in some cases hepatocellular carcinoma. The viral genome comprises a single open reading frame encoding 10 mature proteins: core, E1 and E2 (structural proteins), p7 (a small cation channel), and NS2, NS3, NS4A, NS4B, NS5A and NS5B (non-structural proteins). The development of the subgenomic replicon system (Lohmann et al., 1999; Macdonald et al., 2005b) demonstrated that five of the non-structural proteins (NS3, NS4A, NS4B, NS5A and NS5B) are necessary and sufficient for HCV RNA replication. NS5A is additionally known to interact with a wide range of cellular signalling proteins (Macdonald & Harris, 2004) , indicating a potential role in adapting the host cell to create a more favourable environment for viral replication and the establishment of a chronic infection. In particular, NS5A has been demonstrated to inhibit epidermal growth factor (EGF)-mediated activation of the Ras-Erk signalling pathway (Georgopoulou et al., 2003; Macdonald et al., 2003 Macdonald et al., , 2005b Mankouri et al., 2008; Tan et al., 1999) . This inhibition is mediated via a conserved class II polyproline motif (termed PP2) located towards the C terminus of the protein that interacts with the Src-homology 3 (SH3) domains of proteins such as Grb2 and Src-kinases (Macdonald et al., 2005b) .
The Ras-Erk pathway consists of a tri-partite signalling cascade in which, following receptor autophosphorylation, activated Ras binds to and activates a serine kinase, Raf, which subsequently activates the dual specificity kinases MEK1/2 -these then phosphorylate and activate the Erk1/2 kinases. The latter enter the nucleus and, via phosphorylation of the Elk family transcription factors, upregulate c-Fos expression and concomitantly activate the AP-1 transcription factor. Recent studies in our laboratory (Mankouri et al., 2008) have shown that inhibition of Ras-Erk signalling results from localization of NS5A to early endosomes, where it intercepts the trafficking of EGFreceptor complexes to the late endosome. The precise role that this pathway plays in the virus life cycle remains undetermined, although interestingly a mutation in the PP2 motif (termed PA2) had no effect on either genome replication (Macdonald et al., 2005b) or virus assembly (Hughes et al., 2009) . However, NS5A only partially attenuates Ras-Erk signalling, and it is conceivable that if this signalling was required for replication of viral RNA, the remaining activity might be sufficient for this to fully manifest. To test this hypothesis we analysed HCV genome replication using a transient luciferase subgenomic replicon system in the context of either pharmacological or genetic (dominant-negative, DN) inhibition of Ras-Erk signalling. Our data indicate that, under conditions where Ras-Erk signalling was completely abrogated, there was a significant decrease in viral RNA replication, but no effect on HCV internal ribosome entry site (IRES)-mediated translation was observed. These data suggest that the partial block mediated by NS5A may serve to regulate RNA replication and might play a role in the coordinate regulation of RNA replication and virion assembly.
RESULTS

Perturbation of Ras-Erk signalling occurs in the context of a transient genotype 2a replicon
We have previously shown that NS5A of HCV genotype 1 inhibited Ras-Erk signalling, either when expressed alone or in the context of a culture-adapted subgenomic replicon or full-length HCV expression construct (Macdonald et al., 2003 (Macdonald et al., , 2005a Mankouri et al., 2008) . To test the effects of the Ras-Erk pathway on HCV RNA replication we chose to use the recently developed genotype 2a-based transient luciferase replicon SGR-luc-JFH-1 (Targett- Adams & McLauchlan, 2005) , because this replicon (unlike the genotype 1b versions) demonstrated high levels of replication within a short timescale (,24 h), which would allow quantitative measurement of viral RNA replication in the presence of inhibitors of Ras-Erk signalling.
As we wished to utilize this system to assess the effects of inhibition of the Ras-Erk signalling on replication, we first established that the previously reported downregulation of this pathway also occurred in the context of transient genotype 2a replicon at early time points post-transfection. Levels of phosphorylated (p) Erk1/2 were analysed by Western blotting at 24 h post-transfection (p.t.), in naïve Huh-7.5 cells or cells electroporated with wild-type SGRluc-JFH-1 RNA. After stimulation of the Ras-Erk pathway with EGF a reduction in the levels of pErk1/2 was observed in cells containing the replicon compared with levels detected in naïve Huh-7.5 cells (Fig. 1a) . Total levels of Erk1/2 were unaffected by the presence of the replicon. These data demonstrate that the previously reported reduction in signalling of this pathway takes place at early points in the RNA replication cycle of the virus and is conserved in genotype 2 replicons.
To set a baseline for experiments in which cells transfected with SGR-luc-JFH-1 were treated with pharmacological inhibitors of the Ras-Erk pathway, it was necessary to determine at what point it was possible to distinguish between luciferase activity resulting from translation of input RNA and that accumulated as a result of RNA replication. To do this we undertook a time-course analysis of luciferase activity for both wild-type and replicationdefective GND replicons (Fig. 1b) -this analysis indicated that both wild-type and GND replicons exhibited similar levels of luciferase activity at 8 h p.t., consistent with efficient input translation of the replicon RNA. From 8 to 24 h p.t. there was a large increase in luciferase only for the wild-type replicon, consistent with a period of robust RNA replication, whereas the GND values dropped to baseline. We concluded that treatment of transfected cells between 8 and 24 h p.t. would allow us to assess the effects on RNA replication, independently of translational effects.
Inhibitors of MEK1/2 have differing effects on subgenomic replicon replication Three pharmacological inhibitors of MEK1/2 were selected for use. PD98059, PD184352 and U0126 are structurally distinct non-competitive inhibitors that block the phosphorylation and/or the conformational transition necessary were either left untreated (lanes 1 and 4), incubated with MEK1/2 inhibitor U0126 (20 mm) for 1 h (lanes 2 and 5), prior to 5 min stimulation with 100 ng EGF ml "1 (lanes 2, 3, 5 and 6). Cells were lysed in GLB and analysed via Western blotting with polyclonal antisera to NS5A (Macdonald et al., 2003) , Erk1/2, pErk1/2 or a monoclonal antibody to GAPDH. (b) Time course of SGR-luc-JFH-1 wild-type and GND mutant luciferase levels over 48 h. Huh-7.5 cells were electroporated as previously described and harvested into passive lysis buffer (Promega) at 4, 8, 24 and 48 h p.t. Luciferase activity was measured using a BMG FLUOstar Optima.
for activation of MEK1/2 by upstream kinases (Bain et al., 2007) . Inhibitors were used at recommended concentrations; additionally an MTS assay was performed on Huh-7.5 cells electroporated with SGR-luc-JFH-1 RNA and treated with the inhibitors to confirm that these concentrations did not adversely affect cell viability over a 24 h time period (data not shown). Huh-7.5 cells electroporated with SGR-luc-JFH-1 RNA were incubated from 8 to 24 h p.t. with each inhibitor at five concentrations over a 100-fold range up to the highest viable concentration, prior to harvest and analysis of luciferase activity. Luciferase activity at 4 h p.t. was taken as a baseline (Fig. 2a) . PD98059 treatment resulted in a modest, dose-dependent, increase in levels of replication, surprisingly incubation with U0126 and PD184352 displayed the opposite effect, in that both inhibitors resulted in dose-dependent decreases in luciferase levels at 24 h p.t. In order to confirm that the levels of luciferase activity reflected levels of HCV protein expression, cell lysates were blotted for NS5A, as shown in Fig. 2 (b) levels of NS5A reflected levels of luciferase activity. In order to ensure effects seen with these inhibitors were not artefacts resulting from the use of the interferon cured Huh-7.5 cell line, incubation with the highest concentrations of MEK inhibitors used in Fig. 2 (a) was repeated in Huh-7 cells (Fig. 2c) . As expected replicon replication was lower in Huh-7 cells (Blight et al., 2002) ; however, as in Huh-7.5 cells both U0126 and PD184352 reduced replication levels. Incubation with PD98059 did not result in the increase in replication observed in Huh-7.5 cells, but rather replication levels similar to that of the control (0.01 % DMSO). This may have been a result of the overall decreased levels of replication in these cells. These experiments were also repeated in cells electroporated with pFK5.1luc, a genotype 1b replicon containing a luciferase reporter (Krieger et al., 2001) . Due to the lower replication efficiency of this replicon inhibitors were applied from 56 to 72 h p.t. Results from these experiments (Fig. 2d ) confirmed a modest increase in replication levels in the presence of PD98059, but a modest decrease in the presence of U0126 and PD184352, interestingly the genotype 1b replicon appeared to be less sensitive to the latter two inhibitors.
Due to the discrepant results with PD98059 compared with the other two inhibitors we verified their activity in Huh-7.5 cells: cell lysates were analysed by Western blotting for pErk1/2 after stimulation with EGF (Fig. 2e) . All of the inhibitors showed a decrease in levels of pErk1/2 compared with controls, although interestingly PD98059 was less effective -in particular it did not reduce basal levels of pErk1/2. Blotting for the total levels of Erk1/2 confirmed that the inhibitors had no effect on the abundance of these kinases. The activity of these inhibitors was also tested on cells electroporated with SGR-luc-JFH-1 to ensure that the inhibitors had similar effects in the presence of the subgenomic replicon (Fig. 2f) , as in Fig. 2(e) , all the inhibitors showed a decrease in levels of pErk1/2 compared with controls, but no effect on levels of total Erk1/2.
MEK inhibitors modulate translation from capped RNA and a replication-defective subgenomic replicon
It was conceivable that the observed effects of the MEK inhibitors could be due to modulation of protein translation or stability of viral RNA, rather than direct effects on viral RNA replication. To test this, and further investigate the discrepancy seen between PD98059 and U0126/PD184352, monocistronic reporter constructs were used to investigate the effects of these inhibitors on protein translation. Firstly, a Renilla luciferase (Rluc) RNA was generated from the pRLTK plasmid by in vitro transcription in the presence of a cap analogue. Following transfection of this RNA, cells were harvested at 4 h p.t. to give a baseline, incubated with inhibitors from 8 to 24 h p.t. as described and harvested at 24 h p.t. As shown in Fig. 3(a) there was a net loss of Rluc activity from 4 to 24 h p.t. due to RNA degradation; however, incubation of PD98059 resulted in a twofold increase in Rluc activity compared with control. U0126 had little effect and PD184352 resulted in a twofold decrease.
Unlike the capped Rluc RNA, translation from the subgenomic replicon is driven by both the HCV and encephalomyocarditis virus (EMCV) IRES in a capindependent fashion. We therefore examined the effects of the inhibitors on Rluc translation from non-capped RNAs, containing either the EMCV or HCV IRES at the 59 end. Due to the lack of a cap and inherent instability of these RNAs we were unable to detect significant Rluc activity above background at 24 h p.t. (data not shown). We therefore treated cells with inhibitors immediately p.t. and assayed for luciferase activity at 4 h p.t. Although there were modest differences in the levels of cap-independent translation in the presence of the inhibitors (Fig. 3b, c) these were not significant. Finally, to assess the effect of the inhibitors on translation from a bicistronic replicon RNA we analysed translation of luciferase from the replicationdefective GND replicon (SGR-luc-JFH-1). As shown earlier (Fig. 1b) luciferase expression from this replicon declines dramatically between 4 and 24 h p.t., consistent with the lack of replication and degradation of the RNA. Interestingly, whereas U0126 and PD184352 had little effect on this replicon, treatment with PD98059 resulted in a substantial increase in luciferase activity at all three time points (Fig. 3d-f ). Data from 24 h p.t. showed this increase in luciferase activity was dose-dependent. To determine whether PD98059 blocked degradation of replicon RNA, levels of SGR-luc-JFH-1 (GND) RNA in these cells were assessed by quantitative real time RT-PCR (Hughes et al., 2009) . Overnight incubation in the presence of PD98059 did not correspond with any significant difference in the levels of replicon RNA (data not shown), indicating the increase in luciferase activity observed in Fig. 3(f) was not due to a block in replicon RNA degradation. As PD98059 had no effect on HCV-LUC translation (Fig. 3c) , we propose that this compound may only affect translation of IRES-containing RNAs that also contain the HCV 39 untranslated region. This effect of PD98059 on translation would therefore counteract any inhibitory effect on HCV RNA replication.
Cox-2 inhibitors reduce levels of RNA replication
As a difference in translation did not appear to explain the discrepancy between PD98059 and U0126/PD184352, we questioned whether any off-target effects of these inhibitors might be pertinent. In this regard, PD98059 has been shown to inhibit cyclooxygenases (Cox)-1 and -2 (BorschHaubold et al., 1998), whereas U0126 has not been demonstrated to effect these enzymes. Inhibition of Cox-2 has also been shown to elevate HCV RNA replication (Waris & Siddiqui, 2005) , although this observation is controversial as more recently it was reported that Cox-2 positively contributed to HCV RNA replication (TrujilloMurillo et al., 2008) . We therefore investigated whether inhibition of Cox-2 would explain the discrepancy between inhibitors. Huh-7.5 cells electroporated with SGR-luc-JFH-1 RNA were incubated from 8 to 24 h p.t. with two Cox-2 inhibitors (NS398 and Cox-2 inhibitor III) at concentrations verified to have no cytotoxic effects (data not shown). Both inhibitors decreased replication in a dose-dependent fashion (Fig. 4) , consistent with the recent report (TrujilloMurillo et al., 2008) . As PD98059 inhibits both Cox-2 and MEK we combined both NS398 and PD184352 in an attempt to mimic the effect of PD98059; however, under these conditions we also observed a decrease in replication. These data suggest that the increase in replication seen with PD98059 does not result from an off-target inhibition of Cox-2.
A DN MEK1 mutant inhibits HCV RNA replication
Notwithstanding the discrepant results obtained with PD98059, our data are consistent with a requirement for Ras-Erk signalling in HCV RNA replication. To confirm this we took an alternative approach involving a DN mutant of MEK1, the target of the three inhibitors. A plasmid expressing a MEK1 mutant containing a serine to alanine substitution at residue 217 (thereby preventing phosphorylation by Raf1) (Cowley et al., 1994) was cotransfected with SGR-luc-JFH-1 RNA into Huh-7.5 cells, and luciferase activity was assayed at 4 and 48 h p.t. As shown in Fig. 5(a) , in comparison with control cells transfected with empty vector, the presence of MEK1(S217A) reduced HCV RNA replication in a dosedependent manner. To confirm that MEK1(S217A) was indeed functioning as expected, Huh-7.5 cells were transfected with the expression vector together with an AP-1-luciferase construct (Macdonald et al., 2003) , as shown in Fig. 5 (b) expression of MEK1(S217A) reduced activation of the AP-1-luciferase by sevenfold. This was further confirmed by Western blotting for levels of pErk1/ 2, in cells transfected with either MEK1(S217A) or control vector (Fig. 5c) , where upon stimulation with EGF the expression of MEK1(S217A) resulted in a decrease in levels of pErk1/2 but no effect on total levels of the protein.
DISCUSSION
Previous studies have demonstrated the ability of NS5A of genotype 1 HCV to inhibit signalling of the Ras-Erk pathway (Georgopoulou et al., 2003; Macdonald et al., 2003 Macdonald et al., , 2005a Tan et al., 1999) ; our data show that this ability is conserved by NS5A from the genotype 2a JFH-1 isolate, consistent with the absolute conservation of the class II polyproline motif (PP2) throughout all HCV isolates. Furthermore, this inhibition occurs within the first 24 h p.t., suggesting it is required in the early stages of the viral life cycle.
In this study, we used three pharmacological inhibitors of the Ras-Erk pathway that are well documented for their use in inhibiting MEK1/2 activity to interrogate the role of this critical cell signalling cascade in HCV RNA replication. Although the effects of pharmacological inhibition of the Ras-Erk signalling pathway on HCV RNA replication have been reported previously there are notable discrepancies in the published data. One area of broad agreement is that PD98059 treatment results in an increase in subgenomic replicon replication (Zhu & Liu, 2003; Murata et al., 2005) . Our data mirror this consensus in that PD98059 treatment resulted in a modest increase in subgenomic replicon replication. In contrast, treatment with either U0126 or PD184352, or transfection with a DN form of MEK1, resulted in significant inhibition of replicon replication. These data contrast with two previously published studies (Murata et . Cells were lysed in GLB and Western blotted as indicated. Lanes 1 and 2 contain a control lysate of unstimulated cells and EGF stimulated cells incubated with vehicle (0.01 % DMSO), respectively. (f) Huh-7.5 cells were electroporated with SGR-luc-JFH-1 RNA. Cells (24 h p.t.) were incubated with inhibitors for 1 h prior to 20 min stimulation with 100 ng EGF ml "1 . Cells were lysed in GLB. Lysates were Western blotted as indicated. was shown to stimulate subgenomic replicon replication. However, interpretation of the published data is difficult as in one instance a decrease in luciferase expression from a transient replicon was seen at both low (0.3 mM) and high (10 mM) concentrations of U0126, whereas intermediate concentrations resulted in significant increases (Murata et al., 2005) . In the other study (Huang et al., 2006) , a dose-dependent increase in luciferase levels after incubation of a stable replicon cell line with U0126 (as well as the alternative MEK1/2 inhibitor SL327) was observed. One explanation for this apparent discrepancy is the fact that both of the previously published studies used longer incubation periods, either 72 (Murata et al., 2005) or 48 h (Huang et al., 2006) compared with 16 h used in our study. As neither study conducted a time-course experiment with U0126, it is possible that prolonged incubation with this inhibitor has effects on global translation, thereby resulting in increased IRES-driven translation and therefore luciferase levels.
The discrepancy between the effects of PD98059 and the other two inhibitors cannot be explained by an off-target Fig. 4 . Cox-2 inhibitors reduce replication of SGR-luc-JFH-1. Cells were electroporated with SGR-luc-JFH-1, incubated with Cox-2 inhibitors or a combination of Cox-2 (100 mM NS398) and MEK (2 mM PD184352) inhibitors, and assayed as described in Fig. 2(a) . effect of PD98059 on Cox-2 or stimulation of global translation levels. Recent studies have shown that PD98059 and U0126 act in a similar manner (Davies et al., 2000) , and when screened against 80 protein kinases (Bain et al., 2007) , the only other reported non-specific effect of PD98059 was against MKK5 (Favata et al., 1998) . As U0126 also has activity against this kinase this cannot explain their differences in action. The observation that PD98059 dramatically stimulated luciferase expression from the replication-incompetent GND replicon (Fig. 3) suggests that this compound stimulates HCV RNA replication by an as yet uncharacterized mechanism that involves the stimulation of translation from the replicon RNA.
An alternative explanation may derive from the observation that PD98059 is much less effective in inhibiting Erk1/2 activation than U0126 or PD184352 (Fig. 2e, f) , in particular it did not block basal levels of Erk1/2 phosphorylation. However, titration of U0126 or PD184352 indicated that the increase seen in replication with PD98059 did not result from low (basal) levels of RasErk signalling. At a low concentration of U0126, the pErk1/ 2 level was similar to that observed at a high concentration of PD98059 (Fig. 2f, compare lanes 3 and 6) , indeed at low concentrations of U0126 replicon replication was not inhibited (Fig. 2a) . Our data are thus consistent with the hypothesis that a low level of Ras-Erk signalling is required for RNA replication. However, when Ras-Erk signalling is effectively blocked, for example in the presence of U0126, PD184352 or DN MEK1 (Fig. 5) , this is inhibitory to RNA replication. Of note, the JFH-1 subgenomic replicon was more sensitive to U0126 and PD184352 in Huh-7.5 cells, in which it replicated much more rapidly than in Huh-7 cells. Interestingly, a similar effect was observed with the genotype 1b replicon, suggesting that the high levels of replication of the genotype 2a replicon in Huh-7.5 cells may amplify the effects of the inhibitors.
How might the Ras-Erk signalling pathway influence HCV RNA replication? Ras-Erk signalling regulates an array of cellular processes, including cell cycle progression and translation. Our data show that the reduction in RNA replication levels does not result from an inhibition of translation. However, it has been reported that levels of HCV RNA replication are affected by the stage of the cell cycle (Scholle et al., 2004) , and furthermore, liver biopsies of chronically infected HCV patients show altered expression of cell cycle proteins, suggesting impaired cell cycle progression (Sarfraz et al., 2008) . By perturbing the Ras-Erk signalling pathway, the virus may regulate cell cycle progression to promote RNA replication. MEK1 has been shown to phosphorylate NS5A in vitro (Coito et al., 2004) . It may be possible that the Ras-Erk pathway influences replication by altering the phosphorylation status of NS5A, which has in turn been shown to affect levels of RNA replication (Appel et al., 2005; Neddermann et al., 2004) . However, our data do not support this hypothesis as we did not observe any gross differences in p56/p58 ratio upon inhibitor treatment (see Fig. 1a ).
Data presented in this paper from use of two pharmacological inhibitors of MEK1/2 (PD184352 and U0126) and a DN MEK mutant, both demonstrate that complete inhibition of the Ras-Erk signalling results in a decrease in RNA replication of the HCV subgenomic replicon. HCV is thought to establish a chronic infection in the majority of infected individuals. Perhaps the regulation of RNA replication via the Ras-Erk signalling pathway allows the virus to coordinate RNA replication and virion assembly, or perhaps indicates a mechanism that the virus employs to avoid immune detection and maintain a chronic infection. It is interesting to note a virus which lacks the motif necessary to downregulate this pathway is unable to establish infection in a chimpanzee (Nanda et al., 2006) . It may be that the limitations of short-term culture in highly transformed Huh-7 cells obscure the long-term benefits for HCV of downregulation of this pathway.
METHODS
Cell culture. Huh-7 and Huh-7.5 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % fetal calf serum (FCS), 100 IU penicillin ml
21
, 100 mg streptomycin ml 21 , 1 % non-essential amino acids and 20 mM HEPES buffer.
DNA constructs and manipulations. The generation of the mammalian expression construct pcDNA3.1-MEK(S217A) was achieved by the excision of the BamHI-SalI fragment from pBABEpuroMEK-His LIDA (a kind gift from Chris Marshall, Institute of Cancer Research, London, UK). This fragment was then introduced via BamHI and XhoI sites into pcDNA3.1.
Subgenomic replicon luciferase assay. T7 in vitro transcripts were made from linearized DNA templates of the JFH-1 (SGR-luc-JFH-1) (Targett-Adams & McLauchlan, 2005) and culture-adapted Con1 luciferase subgenomic replicon (FK5.1luc) (Krieger et al., 2001) . Cells at 4610 6 were used per electroporation, they were washed twice in DEPC-treated PBS and resuspended at 1610 7 cells per ml. Replicon RNA (5 mg) was mixed with the cells and electroporated in 0.4 cm cuvettes at 950 mF and 270 V. Cells were resuspended in complete DMEM and 1610 4 cells were seeded into each well of 96-well plates. Cells were lysed directly in 96-well plates by washing with PBS and addition of 16 passive lysis buffer (Promega) per well. Plates were read for luciferase activity using LAR reagent (Promega) on a BMG plate reader, and determined as relative light units (RLU). Inhibitors were obtained as follows: PD98059, NS398 and Cox-2 Inhibitor III (Calbiochem), PD184352 (Professor Philip Cohen, Division of Signal Transduction Therapy, University of Dundee) and U0126 (Upstate).
IRES-driven translation luciferase assays. T7 in vitro transcripts containing either the EMCV or HCV IRES followed by firefly luciferase and a polyadenylation sequence were generated from EcoRI linearized plasmids pEMCV-Luc-AAA and pHCV-Luc-AAA (a kind gift from Theophile Ohlmann, Laboratoire de Virologie Humaine, Lyon, France). A T7 in vitro transcript of BamHI linearized and mung bean nuclease-treated pRLTK (Promega) was generated in the presence of a cap analogue (Ambion). RNA transcript (5 mg) was electroporated into 4610 6 cells as described above.
Co-transfection of plasmid DNA and SGR-JFH-1 RNA. Huh-7.5 cells were seeded into six-well plates. For each well, 1 mg SGR-luc-
